linjc16/ctgov huggingface dataset:
Hormonal and Metabolic Aspects of Endoscopic Sleeve Gastroplasty

Study Overview
=================
Brief Summary
-----------------
The investigators of the study want to investigate the complex interactions between glucose metabolism, food intake/weight loss, and different appetite regulating hormones after ESG in comparison with conventional laparoscopic sleeve gastrectomy (LSG).

Official Title
-----------------
Hormonal and Metabolic Aspects of Endoscopic Sleeve Gastroplasty

Conditions
-----------------
Endoscopic Sleeve Gastroplasty, Laparoscopic Sleeve Gastrectomy, Gut Hormones, Glucose Metabolism Disorders

Intervention / Treatment
-----------------
* Procedure: Endoscopic sleeve gastroplasty
* Procedure: Laparoscopic sleeve gastrectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years Scheduled for endoscopic or laparoscopic sleeve at Hvidovre Hospital HbA1c < 48 mmol/mol before surgery, and no history of diabetes HbA1c < 48 mmol/mol and fasting plasma glucose < 6.1 mmol/l at inclusion BMI<45 Exclusion Criteria: Hemoglobin < 6.5 mmol/l at inclusion Pregnancy or breast feeding Medication affecting the planned examinations

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Endoscopic sleeve gastroplasity operated patients<br>Four test days, two days before surgery, one test day three months after surgery and one test day one year after surgery | Procedure: Endoscopic sleeve gastroplasty<br>* Four-hour solid mixed meal test<br>|
| Other: Laparoscopic sleeve gastrectomy operated patients<br>Four test days, two days before surgery, one test day three months after surgery and one test day one year after surgery | Procedure: Laparoscopic sleeve gastrectomy<br>* Four-hour solid mixed meal test<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in ghrelin (pg/ml) | Changes in ghrelin after a solid meal test compared before and after surgery | 240 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in gut hormone response before and after sugery (pmol/L) |  | 240 minutes |
An Exploratory Study of HRD Score in Chinese Ovarian Cancer Patients Benefiting From PARP Inhibitor Targeted Therapy

Study Overview
=================
Brief Summary
-----------------
This project intends to evaluate the sensitivity of different Homologous Recombination Deficiency (HRD) score to Poly(ADP-ribose) polymerase inhibitor (PARPi) by retrospectively analyzing the tissue samples of patients with ovarian cancer using PARPi, and to determine the cut off value of the HRD score algorithm suitable for the Chinese population, so as to provide evidence for the role of PARPi in ovarian cancer. The screening of the beneficiaries of maintenance therapy provides precise guidance and can be used as a reference for other cancer types.

Official Title
-----------------
An Exploratory Study of HRD Score in Chinese Ovarian Cancer Patients Benefiting From PARP Inhibitor Targeted Therapy

Conditions
-----------------
Ovarian Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age ≥ 18 years; high-grade serous/endometrioid epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer; FIGO stage III or IV; at least 6 cycles and no more than 9 cycles First-line platinum-containing chemotherapy; CR or PR after chemotherapy; ECOG 0-1; sufficient biological samples for HRD score detection; patients signed informed consent; good bone marrow function. Exclusion Criteria: incomplete follow-up records of survival information; unqualified biological sample quality control

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Homologous Recombination Deficiency score | Optimize the Homologous Recombination Deficiency scoring algorithm to calculate the Homologous Recombination Deficiency score of each patient's ovarian cancer tissue | After the ovarian tissue is obtained, an average of 3 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Homologous Recombination Deficiency Score
Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Study P03573)

Study Overview
=================
Brief Summary
-----------------
The object of the study is to determine whether different doses of SCH 530348, when added to standard medical care in persons undergoing percutaneous coronary intervention, will increase the risk of bleeding. A secondary objective is to determine whether patients treated with SCH 530348 have fewer cardiac events such as heart attack, bypass surgery, or death compared with those persons treated with the standard of care.

Official Title
-----------------
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention

Conditions
-----------------
Arterial Obstructive Diseases, Coronary Disease

Intervention / Treatment
-----------------
* Drug: SCH 530348


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A person who is 45 years or older and is mentally competent to provide a signed written informed consent. A person who is scheduled to undergo a percutaneous coronary intervention or a heart catheterization with the intent to undergo a percutaneous coronary intervention. If a woman is of childbearing potential (ie, before menopause), she must test negative for pregnancy and agree to use a reliable method of birth control. Exclusion Criteria: Pregnancy Recent stroke Active internal bleeding or a history of a bleeding disorder Increased risk of bleeding Severe high blood pressure Liver or kidney disease Low platelet count Condition such as alcoholism, mental illness, or drug dependence Ongoing chest pain Planned or ongoing treatment with a blood thinning medication A serious condition or illness that would interfere with participation in the study

Ages Eligible for Study
-----------------
Minimum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: SCH 530348|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of bleeding through the end of treatment in subjects undergoing percutaneous coronary intervention |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of bleeding throughout treatment and follow-up |  |  | 
| Incidence of death and major adverse cardiac events |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Platelets, Platelet Aggregation Inhibitors, Protease-Activated Receptor 1, Hemorrhage
Warming Efficiency of Warm Compresses Versus BLEPHASTEAM® in Eyelid Therapy

Study Overview
=================
Brief Summary
-----------------
The eyelid warming device is designed to relieve the symptoms of dysfunction of the glands in the eyelids Phase I, prospective, comparative study, investigator masked , monocentric Objectives are To assess and compare the warming and moisture of Blephasteam® device versus the warming and moisture of warm and moist compresses. To assess and compare safety on the ocular surface after 10 minutes of Blephasteam® application versus after 10 minutes of warm and moist compresses application

Official Title
-----------------
Phase I, Prospective, Comparative Study, Investigator Masked , Monocentric Measuring Warming Efficiency and Safety of Blephasteam® Versus Warm Compresses in Eyelid Therapy

Conditions
-----------------
Eyelid Diseases

Intervention / Treatment
-----------------
* Device: Warming goggles
* Device: warm and moist compresses


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female aged from 18 to 80 years old. Healthy volunteers. For any contact lens wearers, they must be wearing hydrogel contact lenses (worn at least 3 times per week) Normal ocular examination in both eyes.

Ages Eligible for Study
-----------------
Minimum Age: 4 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Blephasteam Arm<br> | Device: Warming goggles<br> <br> |
| Active Comparator: warm and moist compresses arm<br> | Device: warm and moist compresses<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Temperature measurements | The temperature in the chamber of the goggles for Blephasteam device, or between the lid and the compresses for the moist and warm compress, will be evaluated in 10 consecutive measurements over a period of 10 minutes with a micro sensor at the lower lid margin of one randomly selected eye of 10 randomly selected subjects |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Humidity measurements | The humidity in the chamber of the goggles for Blephasteam device, or between the lid and the compresses for the moist and warm compress, will be evaluated in 10 consecutive measurements over a period of 10 minutes with a micro sensor at the lower lid margin of one randomly selected eye of 10 randomly selected subjects. |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Warming goggles
Recurrence and Patient Satisfaction After Laparoscopic Hernia Repair With Intraperitoneal Onlay-mesh (IPOM)

Study Overview
=================
Brief Summary
-----------------
For laparoscopic ventral hernia repair, the technique to close the hernia gap is not well established. Mainly three techniques are currently applied: no closure at all extracorporal suturing of the gap intracorporal suturing of the gap All three techniques have been applied at our hospital. Patients who received laparoscopic hernia repair between 2006 and 2011 will be identified from the patient database and will be contacted by phone to inquire about the outcome and the satisfaction of the surgery.

Official Title
-----------------
Recurrence and Patient Satisfaction After Laparoscopic Hernia Repair With Intraperitoneal Onlay-mesh (IPOM)

Conditions
-----------------
Ventral Hernia, Recurrent Ventral Hernia

Intervention / Treatment
-----------------
* Procedure: hernia gap closure
* Procedure: extracorporal suturing of gap


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hernia repair between 2006 and 2011 laparoscopic hernia repair using intraperitoneal onlay-mesh (IPOM) patient agrees to be surveyed by phone Exclusion Criteria: Patient rejects participation in survey patient already rejected use of his/her data for research purposes at admittance to surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| no gap closure<br>no hernia gap closure | |
| extracorporal gap closure<br>extracorporal hernia gap closure extracorporal suturing of gap | Procedure: hernia gap closure<br>* type of gap closure during laparoscopic repair of a ventral hernia: none, extracorporal, intracorporal<br>Procedure: extracorporal suturing of gap<br>* ventral hernia gap is sutured extracorporally<br>|
| intracorporal gap closure<br>intracorporal hernia gap closure | Procedure: hernia gap closure<br>* type of gap closure during laparoscopic repair of a ventral hernia: none, extracorporal, intracorporal<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrence rate | Hernia recurrence at the time of phone survey (2 - 7 years after surgery) | 7 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to recurrence | time from surgery to hernia recurrence | 7 years | 
| Patient satisfaction | questionnaire with 4 items and 5 step Likert scales | 2 - 7 years after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hernia, Ventral
Quality of Life of Taiwan People Living With HIV

Study Overview
=================
Brief Summary
-----------------
To survey QoL and relevant factors in PLWH

Official Title
-----------------
Investigation on Quality of Life and Related Factors of Taiwan People Living With HIV

Conditions
-----------------
HIV-1-infection

Intervention / Treatment
-----------------
* Other: none of intervention was given


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult patient living with HIV, aged >= 18 years old Exclusion Criteria: known cognitive dysfunction or attention deficient to complete the survey

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: none of intervention was given|this is an observational survey and no intervention is given|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| QoL status of Patient Living with HIV (PLWH) by WHOQOL-HIV Brief questionaire |  | in 4 weeks | 
| Medical Outcome of Patient Living with HIV (PLWH) by MOS-HIV questionaire |  | in 4 weeks | 
| Stigma Scale of Patient Living with HIV (PLWH) by Berger's HIV Stigma Scale |  | an average of 1 year |
Registry on Salvage Antiviral Treatment for Patients Experiencing ADV and / or CMV Reactivation Post Allogeneic HSCT

Study Overview
=================
Brief Summary
-----------------
DESIGN: Disease registry - non-interventional. INDICATION: Patients failing first or subsequent line treatment for adenovirus and / or cytomegalovirus reactivation post allogeneic hematopoietic stem cell transplantation.

Detailed Description
-----------------
In this disease registry, data on approximately 120 allo HSCT patients who have received salvage treatment (second or later line) with any antiviral therapy for ADV and / or CMV post allogeneic HSCT will be documented; of these 120, at least 40 patients will have been treated with Cell Medica's immune reconstitution ACT as salvage therapy. The patients will be consented prospectively or retrospectively for collection of data. Data will be collected at baseline, 6 months and 1 year after commencement of salvage treatment. Retrospective data collection (for patients who underwent HSCT in 2010 or later) is permitted.

Official Title
-----------------
European Patient Registry on Salvage Antiviral Treatment for Patients Experiencing Adenovirus and / or Cytomegalovirus Reactivation Post Allogeneic Hematopoietic Stem Cell Transplantation

Conditions
-----------------
Infectious Complications Following HSCT

Intervention / Treatment
-----------------
* Other: antiviral therapies for CMV and/or ADV


Participation Criteria
=================
Eligibility Criteria
-----------------
Written informed consent Physician requested salvage (defined as refractory to first, requirement for second line or greater) treatment for ADV and / or CMV reactivation post allogeneic HSCT.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: antiviral therapies for CMV and/or ADV|salvage antiviral treatments for ADV and/or CMV|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ADV and/or CMV reactivations | assessment of ADV/CMV viral clearance to evaluate the efficacy of salvage therapies for ADV and / or CMV infections post allogeneic HSCT | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ADV, CMV, HSCT
Morphofunctional Lung Analysis by PET and CT After Lung Transplantation

Study Overview
=================
Brief Summary
-----------------
72 hours after lung transplantation, patients undergo a positron emission tomography (PET) scan and a computed tomography (CT) scan in order to analyse lung function and morphology. Aim of the study is to analyse complications onset (in particular primary graft dysfunction), and evaluate 90 days mortality after lung transplantation.

Detailed Description
-----------------
Pulmonary transplantation is considered as a lifesaving procedure in end-stage pulmonary disease. However morbidity and mortality after lung transplantation are still significant. Primary graft dysfunction (PGD) is the main cause of early death. PGD is similar to acute lung injury (ALI)/ acute respiratory distress syndrome (ARDS): oxygenation is compromised, pulmonary compliance is decreased, chest Rx shows several infiltrates, and alveolar damage is present. 25% of patients develops PGD within 72 hours from transplantation and 30 days mortality is eight times higher in patients who develop PGD. 72 hours after lung transplantation, patients, whose clinical condition allow to bring them to nuclear medicine department, will undergo pulmonary computed tomography (CT) to study lung morphology and measure lung recruitability and positron emission tomography (PET) to study lung functionality and estimate lung inflammation. Aim of this study is to investigate the onset of PGD and other complications and to determine 72 hours and 90 days mortality after lung transplantation.

Official Title
-----------------
Morphofunctional Lung Analysis by Positron Emission Tomography and Computed Tomography After Lung Transplantation

Conditions
-----------------
Disorder Related to Lung Transplantation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: lung transplantation ≥ 18 years Exclusion Criteria: < 18 years patient' s clinical conditions not allowing patient transport from ICU to Nuclear Medicine Unit

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Lung transplantated patients<br>Patients undergone lung transplantation | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients alive |  | up to 90 days from transplantation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of complications other than primary graft dysfunction |  | 72 hours and 90 days | 
| incidence of primary graft dysfunction |  | 72 hours and 90 days after transplantation |
Efficacy of Proton Pump Inhibitor for Chronic Cough Caused by Gastroesophageal Reflux; Double-blind, Placebo-controlled, Randomized Clinical Trial

Study Overview
=================
Brief Summary
-----------------
Efficacy of proton pump inhibitor for chronic cough caused by gastroesophageal reflux; double-blind, placebo-controlled, randomized clinical trial

Conditions
-----------------
Chronic Cough Caused by Gastroesophageal Reflux

Intervention / Treatment
-----------------
* Drug: High-dose PPI
* Drug: standard PPI
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ages of 18 and 70 years had chronic cough of >8 weeks in duration Exclusion Criteria: 1. abnormal chest X ray, PNS view 2. previous surgical or endoscopic antireﬂux procedure 3. previous aerodigestive malignancy or Barrett's oesophagus 4. current smokers or ex-smok-ers (deﬁned as those who quit smoking <3 months prior to study enrolment or those who have quit, but have a 20 pack year smoking history) 5. Malignancy History (lung cancer, esophageal cancer etc.) 6. upper respiratory infection within 8 weeks of study enrolment 7. currently using a PPI, H2 blocker, beta-blocker, angiotensin-converting enzyme inhibitor, corticosteroid, methylxanthine, inhaled beta-agonist, anti-inﬂammatory agent or anticholinesterase drug at time of enrolment

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: arm1-High dose PPI<br> | Drug: High-dose PPI<br>* :40mg, po(per oral) 2times.day, 8weeks<br>|
| Active Comparator: arm2-standard dose PPI<br> | Drug: standard PPI<br>* : 40mg, po(per oral) 1times.day, 8weeks<br>|
| Placebo Comparator: arm3-placebo<br>Esomeprazole placebo | Drug: placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in LCQ score and cough VAS, comparing PPI-treated group to placebo |  | change in LCQ score after 4 weeks and 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in LCQ score and cough VAS, comparing PPI-treated group to placebo |  | change in cough VAS after 4weeks and 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic cough, proton pump inhibitor, GERD, nonacid reflux,